Gujarat, INDIA (June 2026) – Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), a pharmaceutical API manufacturing and drug development company, successfully completed an inspection by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, at its Naroda manufacturing facility.

DCAL is pleased to announce the successful completion of an inspection by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, at its Naroda manufacturing site.

The successful inspection reflects the continued strength of the site's quality management systems, regulatory compliance framework, and operations. It reinforces the company's commitment to maintaining the highest standards of quality, patient safety, and Good Manufacturing Practices (GMP).

"The successful completion of the MFDS inspection underscores our unwavering commitment to quality, compliance, and operational excellence. This achievement also reflects the dedication and expertise of our teams, whose relentless focus enables us to consistently meet the best standards expected by global regulatory authorities and customers. This milestone also reinforces our global footprint and enhances our ability to accelerate growth across the APAC region, underpinned by trust and long-term partnerships.”

— [Paolo Armanino], Chief Operating Officer, DCAL

As a trusted global partner to the pharmaceutical industry, DCAL remains focused on continuously enhancing its capabilities while delivering reliable and compliant solution worldwide aimed at patient safety and customer success.

AHMEDABAD, India (June 13, 2025) - Dishman Carbogen Amcis Ltd’ Naroda manufacturing facility went through an inspection by the USFDA between 9th to 12th June, 2025, which was concluded without any observations, confirming that no concerns were identified.

Paolo Armanino, COO of Dishman Carbogen Amcis Ltd, spoke about the company's achievement regarding the recent USFDA inspection: 

"Once again, the successful completion of the USFDA inspection, without observations, of our Naroda manufacturing facility reaffirms our organisation’s commitment to consistently maintaining the highest quality standards over time.  

 I want to extend my heartfelt congratulations to all team members for their dedication and hard work. I am also extremely proud of all our subject matter experts across India who supported the pre-inspection activities. 

 The successful inspection at Naroda, along with last year's approvals from PMDA Japan, EDQM/AIFA, and the USFDA for our Bavla site, underscores Dishman Carbogen Amcis Ltd’ track record of delivering high-quality manufacturing services. 

 I would like to take this opportunity to sincerely appreciate the company’s promoters, who have been instrumental and played a crucial role in supporting the quality strategy. Their efforts have ensured that all Dishman group pharma facilities are established and maintained according to the highest international standards.”  

****

Dishman Carbogen Amcis Ltd (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, in China and in India.

CARBOGEN AMCIS (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Ltd, Ahmedabad, India.

OTHER NEWS

NEW DELHI, India, (April 18, 2024) – Dishman Carbogen Amcis Ltd received the Choose France-Best Indian Investment in France award by the Indo French Chamber of Commerce & Industry in partnership with Business France India, at the sixth flagship event of the Indo-French Business Awards (IFBA) and Grand Prix VIE, in New Delhi. His Excellency Mr. Thierry Mathou, Ambassador of France presented the award which recognises Dishman’s investment in a new state-of-the-art facility in Saint Beauzire, France, and the increase in Human Capital over the last few years.

Giving a detailed overview of the company's facility in Saint Beauzire and future business plans, Mr. Harshil Dalal, Group CFO - Dishman Group, stated:

“We thank the Indo French Chamber of Commerce and Industry for this wonderful recognition of our efforts to make France our destination of choice to do business."

Dishman Carbogen Amcis Ltd stands as a beacon of innovation and progress in the healthcare industry, transcending borders with our multi-site transcontinental presence. With 11 manufacturing sites and 6 sales offices spread across 6 countries, and subsidiaries in key regions like Switzerland, France, Netherlands, UK, and China, we're poised to deliver comprehensive healthcare solutions like never before.

Our journey in France epitomizes our commitment to growth and excellence. In 2012, we acquired a small but promising company, igniting a transformative journey in the realm of Sterile Investigational Medicinal Products (IMPS). Specializing in complex compounds, this facility became a nucleus for innovation, crafting aseptic drug products for preclinical and clinical batches in various forms.

Fast forward to 2023, a milestone year as we inaugurated our state-of-the-art facility in Saint Beauzire. With a Euro 58 million investment, this cutting-edge 9500 m2 establishment symbolizes our dedication to pushing boundaries. Operational since October 2023, it hosts over 100 skilled professionals, a testament to our commitment to job creation and skill development.

Our growth trajectory is not just about numbers; it's about impact. From a modest headcount of 34 in 2018-19, we've surged to 120 by March 2024, with sights set on reaching 200 by March 2028. This expansion isn't just about revenue; it's about societal contribution. From Euro 5 million annually to a projected Euro 40 million, our growth isn't just corporate—it's communal.

Beyond financial gains, our France site embodies potential. It's a gateway to new markets, a hub for R&D, and a catalyst for groundbreaking therapies like anti-cancer drugs. As we expand, so does our organizational backbone, with 70 new positions created, heralding a future brimming with opportunities.

Reflecting on our journey, we've come a long way from our humble beginnings. Yet, amidst our growth, the most profound transformation is the confidence we hold in the future—a future shaped by relentless innovation, unwavering dedication, and boundless potential."

Gujarat, India - After a successful on-site inspection, Ahmedabad-based Dishman Carbogen Amcis Ltd (DCAL), receives the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) certification.

DCAL’s drug substances manufacturing facility located in Bavla, underwent an inspection by the Japanese Health Authority. We are glad to announce that the inspection ended satisfactorily, and no major or critical observations were reported. As a result, PMDA recently awarded the company with the certification of GMP compliance. We are proud of this achievement which is an acknowledgement of our efforts toward maintaining current Good Manufacturing Practices (cGMPs). This certification reaffirms our commitment to improving the health of people all over the world.

We take this opportunity to heartily congratulate our teams and laud their sincerity and dedication that led to this positive outcome.

Speaking about the PMDA certification, here is what our COO, Mr. Paolo Armanino, said: “First of all, we would like to thank PMDA for their time and invaluable feedback. We feel proud to continue to be approved by the Japanese Authority. I would also like to extend my heartfelt congratulations to all the team who made this remarkable achievement possible.

We maintain strategic ties with our Japanese customers, and we recognize the company's responsibility to work closely together to improve patient health and safety. Dishman Carbogen Amcis Ltd supplies several critical drugs to the Japanese market, and we see several significant and positive developments in our business in the upcoming years.

Going forward, we aim to further expand our services and products portfolio in Japan to fulfil the customer’s needs. In order to closely engage with the demands and requirements of the Japanese market, we are thrilled to be visiting Tokyo in a few weeks for CPHI Japan, and look forward to meeting our existing and prospective valuable customers and partners.